Redwood AI Partners with Resilience Biosciences to Tackle Opioid Withdrawal with AI-Powered Chemistry

Redwood AI and Resilience Biosciences join forces to use AI computational chemistry for non-opioid addiction and pain treatments, targeting a $12.6B market by 2034.

The race to bring non-opioid treatments for addiction and pain to market is drawing serious firepower from artificial intelligence. Redwood AI has announced a clinical-stage collaboration with Vancouver-based Resilience Biosciences Inc. (RBI), a biopharma company focused on developing therapies for opioid withdrawal, withdrawal-associated pain, and cognitive deficits.

Under the terms of the deal, Redwood will deploy its proprietary AI platform for computational chemistry to accelerate RBI’s drug discovery pipeline. The software handles retrosynthetic analysis, derivative generation, and IP-aware workflow checks — all aimed at shortening the journey from molecule concept to a development-ready candidate. “We want to compress the timeline from idea to candidate,” Redwood CEO Louis Dron said in a statement.

A Market Ready for AI-Driven Discovery

The timing of the partnership aligns with explosive growth projections for AI in drug development. The global market for AI-powered drug discovery is estimated at roughly $5 billion in 2026, and analysts forecast it will nearly triple to $12.6 billion by 2034, representing a compound annual growth rate of more than 12%. Small molecules — the category targeted by the Resilience collaboration — are seen as the segment leading that expansion.

That broader appetite for AI in pharma is underscored by recent capital flows. In May 2026, Nvidia invested $10.4 million in Generate Biomedicines, a sign that institutional investors view 3D molecular modeling and closed-loop AI workflows as mature technologies rather than experimental concepts.

Building an Integrated Non?Opioid Platform

For Resilience, the partnership is part of a broader strategy to construct an integrated translational platform for next-generation therapeutics. Matthew Roberts, Chief Operations Advisor at Resilience, noted the deal bolsters the scientific and operational backbone behind the company’s growing non-opioid portfolio. CEO Prof. Anthony Phillips added that the collaboration strengthens RBI’s in-house capabilities at a time when the medical need for alternatives to opioids is acute.

Redwood, meanwhile, is running a parallel AI-driven Alzheimer’s project with the University of British Columbia. The Resilience deal is not the only news from a busy May. On May 14, Redwood announced a new optimization module within its Reactosphere platform, designed to help chemists improve experimental outcomes. Around the same time, a wholly owned Redwood subsidiary secured up to 240,000 Canadian dollars from the National Research Council of Canada for Project Q?SAFE, a quantum?based classification system for chemical hazards.

Market Reaction and What Comes Next

The Resilience partnership was announced on May 22, and Redwood’s shares closed the following trading day — Friday, May 24 — at €5.98 on the Frankfurt exchange, up just over 1%. While modest, the gain suggests investors are taking a wait-and-see approach. No near-term quarterly report is scheduled, according to company sources, meaning the focus for the coming weeks will be on whether the non-opioid positioning attracts further interest from the life?sciences investment community.

For now, Redwood AI has strung together an unusually dense month of announcements. The real test will be whether that activity translates into tangible commercial traction — a question the market is likely to keep asking until the pipeline delivers more concrete milestones.